Top

Current Hepatology Reports

Published in:

01-12-2018 | Fatty Liver Disease (Z Younossi, Section Editor)

The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality

Authors: Ramy Younes, Elisabetta Bugianesi

Published in: Current Hepatology Reports | Issue 4/2018

Abstract

Purpose of Review

In this review, we examine the interaction between the metabolic syndrome (MS) and non-alcoholic fatty liver disease (NAFLD) and describe the impact of the features of MS on the most worrisome complications of non-alcoholic steatohepatitis (NASH), (cirrhosis, hepatocellular carcinoma) and, ultimately, on liver-related, cardiovascular, and overall mortality.

Recent Findings

Insulin resistance, obesity, and dyslipidemia in a pro-inflammatory environment have a causal role in hepatic fibrogenesis and oncogenesis in NAFLD patients. Natural history, longitudinal studies confirm the conditions linked to MS as independent predictors of overall-, cardiovascular-, and liver-related mortality.

Summary

Dysmetabolic factors stemming from insulin resistance play a key role in liver damage progression. Obesity, type 2 diabetes (T2DM), dyslipidemia, and arterial hypertension are independent predictors of liver fibrosis and cirrhosis; furthermore, obesity and T2DM play a key role in the development of hepatocellular carcinoma both in cirrhotic and non-cirrhotic NASH patients.

Younossi ZM. The epidemiology of nonalcoholic steatohepatitis. Clin Liver Dis. 2018;11(4):92–4. https://doi.org/10.1002/cld.710.CrossRef

Bhala N, Younes R, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des. 2013;19(29):5169–76. https://doi.org/10.2174/13816128113199990336.CrossRefPubMed

Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97.CrossRef

Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–5.CrossRefPubMed

Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792–8. https://doi.org/10.1002/hep.22429.CrossRefPubMed

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23. https://doi.org/10.1053/jhep.2003.50161.CrossRefPubMed

van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48(2):449–57. https://doi.org/10.1002/hep.22350.CrossRefPubMed

Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes. 2006;55(6):1554–61. https://doi.org/10.2337/db06-0133.CrossRefPubMed

Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology. 2006;130(6):1848–52. https://doi.org/10.1053/j.gastro.2006.03.041.CrossRefPubMed

10.

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38. https://doi.org/10.1056/NEJMoa021423.CrossRefPubMed

11.

Berentzen TL, Gamborg M, Holst C, Sorensen TI, Baker JL. Body mass index in childhood and adult risk of primary liver cancer. J Hepatol. 2014;60(2):325–30. https://doi.org/10.1016/j.jhep.2013.09.015.CrossRefPubMed

12.

Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97(7):1005–8. https://doi.org/10.1038/sj.bjc.6603932.CrossRefPubMedPubMedCentral

13.

McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148–55. https://doi.org/10.1016/j.jhep.2014.11.034.CrossRefPubMed

14.

Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies. Hepatol Commun. 2018;2(2):199–210. https://doi.org/10.1002/hep4.1134.CrossRefPubMed

15.

•• Petta S, Eslam M, Valenti L, Bugianesi E, Barbara M, Camma C, et al. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: an age-dependent risk profiling study. Liver Int. 2017;37(9):1389–96. https://doi.org/10.1111/liv.13397. Important study on the effects of the metabolic syndrome on NAFLD outcomes. CrossRefPubMed

16.

Koh WP, Wang R, Jin A, Yu MC, Yuan JM. Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer. 2013;108(5):1182–8. https://doi.org/10.1038/bjc.2013.25.CrossRefPubMedPubMedCentral

17.

Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166(17):1871–7. https://doi.org/10.1001/archinte.166.17.1871.CrossRefPubMed

18.

Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol. 2010;45(7):750–7. https://doi.org/10.1007/s00535-010-0203-y.CrossRefPubMed

19.

Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015;21(25):7860–8. https://doi.org/10.3748/wjg.v21.i25.7860.CrossRefPubMedPubMedCentral

20.

Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol. 2010;105(2):336–44. https://doi.org/10.1038/ajg.2009.587.CrossRefPubMed

21.

Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–54 e1–9; quiz e39–40. https://doi.org/10.1016/j.cgh.2014.04.014.CrossRefPubMed

22.

Jorge ASB, Andrade JMO, Paraiso AF, Jorge GCB, Silveira CM, de Souza LR, et al. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity. Obes Res Clin Pract. 2018;12:1S1):1–8. https://doi.org/10.1016/j.orcp.2016.03.009.CrossRef

23.

Kazankov K, Barrera F, Moller HJ, Rosso C, Bugianesi E, David E, et al. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver Int. 2016;36(10):1549–57. https://doi.org/10.1111/liv.13150.CrossRefPubMed

24.

Lallukka S, Sevastianova K, Perttila J, Hakkarainen A, Orho-Melander M, Lundbom N, et al. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia. 2013;56(4):886–92. https://doi.org/10.1007/s00125-013-2829-9.CrossRefPubMed

25.

Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015;15(6):607. https://doi.org/10.1007/s11892-015-0607-4.CrossRefPubMed

26.

Pelusi S, Petta S, Rosso C, Borroni V, Fracanzani AL, Dongiovanni P, et al. Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression: an observational study in patients with nonalcoholic fatty liver disease. PLoS One. 2016;11(9):e0163069. https://doi.org/10.1371/journal.pone.0163069.CrossRefPubMedPubMedCentral

27.

Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–52. https://doi.org/10.1016/j.jhep.2017.09.021.CrossRefPubMed

28.

Miyaaki H, Ichikawa T, Nakao K, Yatsuhashi H, Furukawa R, Ohba K, et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int. 2008;28(4):519–24. https://doi.org/10.1111/j.1478-3231.2007.01614.x.CrossRefPubMed

29.

Ono M, Ochi T, Munekage K, Ogasawara M, Hirose A, Nozaki Y, et al. Angiotensinogen gene haplotype is associated with the prevalence of Japanese non-alcoholic steatohepatitis. Hepatol Res. 2011;41(12):1223–9. https://doi.org/10.1111/j.1872-034X.2011.00883.x.CrossRefPubMed

30.

Noguchi R, Yoshiji H, Ikenaka Y, Kaji K, Shirai Y, Aihara Y, et al. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. Int J Mol Med. 2010;26(3):407–13.PubMed

31.

Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11(2):183–90. https://doi.org/10.1038/nm1166.CrossRefPubMedPubMedCentral

32.

Artunc F, Schleicher E, Weigert C, Fritsche A, Stefan N, Haring HU. The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol. 2016;12(12):721–37. https://doi.org/10.1038/nrneph.2016.145.CrossRefPubMed

33.

Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32(1):22–9. https://doi.org/10.1055/s-0032-1306423.CrossRefPubMedPubMedCentral

34.

Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109–23. https://doi.org/10.1016/j.metabol.2016.05.003.CrossRefPubMed

35.

Kantartzis K, Rittig K, Cegan A, Machann J, Schick F, Balletshofer B, et al. Fatty liver is independently associated with alterations in circulating HDL2 and HDL3 subfractions. Diabetes Care. 2008;31(2):366–8. https://doi.org/10.2337/dc07-1558.CrossRefPubMed

36.

Sonmez A, Nikolic D, Dogru T, Ercin CN, Genc H, Cesur M, et al. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. J Clin Lipidol. 2015;9(4):576–82. https://doi.org/10.1016/j.jacl.2015.03.010.CrossRefPubMed

37.

Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37(4):909–16. https://doi.org/10.1053/jhep.2003.50132.CrossRefPubMed

38.

Pardina E, Baena-Fustegueras JA, Llamas R, Catalan R, Galard R, Lecube A, et al. Lipoprotein lipase expression in livers of morbidly obese patients could be responsible for liver steatosis. Obes Surg. 2009;19(5):608–16. https://doi.org/10.1007/s11695-009-9827-5.CrossRefPubMed

39.

Miksztowicz V, Lucero D, Zago V, Cacciagiu L, Lopez G, Gonzalez Ballerga E, et al. Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. Diabetes Metab Res Rev. 2012;28(6):535–41. https://doi.org/10.1002/dmrr.2312.CrossRefPubMed

40.

Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63(3):705–12. https://doi.org/10.1016/j.jhep.2015.05.006.CrossRefPubMed

41.

Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–40.CrossRefPubMed

42.

Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? J Hepatol. 2018;68(2):326–34. https://doi.org/10.1016/j.jhep.2017.10.006.CrossRefPubMed

43.

McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity. 2014;41(1):36–48. https://doi.org/10.1016/j.immuni.2014.05.010.CrossRefPubMed

44.

Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–46. https://doi.org/10.1146/annurev-physiol-021909-135846.CrossRefPubMed

45.

•• Reeves HL, Zaki MY, Day CP. Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD. Dig Dis Sci. 2016;61(5):1234–45. https://doi.org/10.1007/s10620-016-4085-6. Outstanding review on pathophysiological mechanisms underpinning metabolic syndrome and HCC in NAFLD. CrossRefPubMed

46.

Zimmet P, Hodge A, Nicolson M, Staten M, de Courten M, Moore J, et al. Serum leptin concentration, obesity, and insulin resistance in Western Samoans: cross sectional study. BMJ. 1996;313(7063):965–9.CrossRefPubMedPubMedCentral

47.

de Courten M, Zimmet P, Hodge A, Collins V, Nicolson M, Staten M, et al. Hyperleptinaemia: the missing link in the, metabolic syndrome? Diabet Med. 1997;14(3):200–8. https://doi.org/10.1002/(SICI)1096-9136(199703)14:3<200::AID-DIA336>3.0.CO;2-V.CrossRefPubMed

48.

Wauters M, Considine RV, Yudkin JS, Peiffer F, De Leeuw I, Van Gaal LF. Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion. Horm Metab Res. 2003;35(2):92–6. https://doi.org/10.1055/s-2003-39054.CrossRefPubMed

49.

Wang SN, Lee KT, Ker CG. Leptin in hepatocellular carcinoma. World J Gastroenterol. 2010;16(46):5801–9.CrossRefPubMedPubMedCentral

50.

Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7(8):947–53. https://doi.org/10.1038/90992.CrossRefPubMed

51.

Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C, et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology. 2010;139(5):1762–73, 73 e1–5. https://doi.org/10.1053/j.gastro.2010.07.001.CrossRefPubMed

52.

Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 2010;52(5):1713–22. https://doi.org/10.1002/hep.23892.CrossRefPubMed

53.

Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol. 2014;26(1):100–7. https://doi.org/10.1097/CCO.0000000000000042.CrossRefPubMedPubMedCentral

54.

Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev. 2010;90(4):1383–435. https://doi.org/10.1152/physrev.00030.2009.CrossRefPubMed

55.

Aghajan M, Li N, Karin M. Obesity, autophagy and the pathogenesis of liver and pancreatic cancers. J Gastroenterol Hepatol. 2012;27(Suppl 2):10–4. https://doi.org/10.1111/j.1440-1746.2011.07008.x.CrossRefPubMedPubMedCentral

56.

Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma. Gastroenterology. 2015;149(1):119–29. https://doi.org/10.1053/j.gastro.2015.03.044.CrossRefPubMed

57.

Archambeaud I, Auble H, Nahon P, Planche L, Fallot G, Faroux R, et al. Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis: the importance of prior obesity. Liver Int. 2015;35(7):1872–6. https://doi.org/10.1111/liv.12767.CrossRefPubMed

58.

Schlesinger S, Aleksandrova K, Pischon T, Fedirko V, Jenab M, Trepo E, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer. 2013;132(3):645–57. https://doi.org/10.1002/ijc.27645.CrossRefPubMed

59.

Marble A. Diabetes and cancer. N Engl J Med. 1934;211(8):339–49. https://doi.org/10.1056/nejm193408232110801.CrossRef

60.

Lawson DH, Gray JM, McKillop C, Clarke J, Lee FD, Patrick RS. Diabetes mellitus and primary hepatocellular carcinoma. Q J Med. 1986;61(234):945–55.PubMed

61.

Kasmari AJ, Welch A, Liu G, Leslie D, McGarrity T, Riley T. Independent of cirrhosis, hepatocellular carcinoma risk is increased with diabetes and metabolic syndrome. Am J Med. 2017;130(6):746.e1–7. https://doi.org/10.1016/j.amjmed.2016.12.029.CrossRef

62.

Joost HG. Diabetes and cancer: epidemiology and potential mechanisms. Diab Vasc Dis Res. 2014;11(6):390–4. https://doi.org/10.1177/1479164114550813.CrossRefPubMed

63.

Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Research. 2018;2:43–51. https://doi.org/10.1016/j.livres.2017.11.005.CrossRefPubMedPubMedCentral

64.

Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. San Antonio Heart S. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110(10):1251–7. https://doi.org/10.1161/01.CIR.0000140762.04598.F9.CrossRefPubMed

65.

Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2003;168(2):351–8.CrossRefPubMed

66.

Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769–78.CrossRefPubMed

67.

•• Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97(13):e0214. https://doi.org/10.1097/MD.0000000000010214. Interesting and important study, analysing the impact of MS components on mortality in patients with NAFLD. CrossRef

68.

Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58(10):3017–23. https://doi.org/10.1007/s10620-013-2743-5.CrossRefPubMed

69.

Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234–8. https://doi.org/10.1016/j.cgh.2008.11.005.CrossRefPubMed

70.

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397.e10. https://doi.org/10.1053/j.gastro.2015.04.043.CrossRefPubMed

71.

Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–21.CrossRefPubMed

72.

Younes R, Rosso C, Petta S, Cucco M, Marietti M, Caviglia GP, et al. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: an external validation study. Liver Int. 2017;38:715–23. https://doi.org/10.1111/liv.13612.CrossRefPubMed

73.

Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017;15:11–20. https://doi.org/10.1038/nrgastro.2017.109.CrossRefPubMed

74.

Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149(2):379–88; quiz e15–6. https://doi.org/10.1053/j.gastro.2015.04.014.CrossRefPubMed

75.

European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. https://doi.org/10.1016/j.jhep.2015.11.004.CrossRef

Title: The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality
Authors: Ramy Younes
Elisabetta Bugianesi
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Hepatology Reports / Issue 4/2018
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-018-0422-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2018

Hepatitis B Reactivation in the DAA Era: Minding the Gap Between the Black Box and Clinical Practice

Current State of Immunotherapy for HCC—Supporting Data and Toxicity Management

New Advances in Hepatitis B Vaccination for Adults

The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Implications of Circulating Hepatitis B Virus RNA Levels in Assessment of Response to Antiviral Therapy

Portal Cavernoma Cholangiopathy

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage